La vendita allo scoperto per Biogen dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Biogen. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Biogen (NASDAQ:BIIB) Azioni, Report sulle vendite allo scoperto

Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Inc

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $251 to $207.

News

Price Target

Analyst Ratings

BIIB

Mizuho Maintains Outperform on Biogen, Lowers Price Target to $207

Investors with a lot of money to spend have taken a bearish stance on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BIIB, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Biogen.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $198,898, and 4 are calls, for a total amount of $138,060.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $130.0 to $200.0 for Biogen over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Biogen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Biogen's substantial trades, within a strike price spectrum from $130.0 to $200.0 over the preceding 30 days.
<h3>Biogen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732131069_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$2.35</td>
<td>$1.35</td>
<td>$2.0</td>
<td>$155.00</td>
<td>$60.0K</td>
<td>1.5K</td>
<td align="right">663</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$22.6</td>
<td>$18.3</td>
<td>$19.32</td>
<td>$150.00</td>
<td>$48.3K</td>
<td>0</td>
<td align="right">25</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$29.6</td>
<td>$21.7</td>
<td>$24.0</td>
<td>$180.00</td>
<td>$48.0K</td>
<td>111</td>
<td align="right">20</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$8.6</td>
<td>$7.8</td>
<td>$8.6</td>
<td>$175.00</td>
<td>$35.2K</td>
<td>19</td>
<td align="right">4</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$2.1</td>
<td>$1.55</td>
<td>$2.09</td>
<td>$155.00</td>
<td>$33.5K</td>
<td>1.5K</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Following our analysis of the options activities associated with Biogen, we pivot to a closer look at the company's own performance.
<h3>Where Is Biogen Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 839,529, with BIIB's price down by -0.49%, positioned at $154.67.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for Biogen</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $261.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $270. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Biogen with a target price of $255. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $270. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Biogen, which currently sits at a price target of $300. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Biogen, targeting a price of $210. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Biogen Unusual Options Activity For November 20

On Tuesday, UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) and&nbsp;Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42054524/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significa" rel="noreferrer noopener">systemic lupus erythematosus</a>.
The drug candidate demonstrated significant clinical improvement in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41000544/biogenucb-partnered-autoimmune-disease-candidate-hits-primary-goal-in-late-stage-study-sets-stage" rel="noreferrer noopener">Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial</a>
The results were shared at the American College of Rheumatology&#8217;s annual meeting. In the 321-subject trial, DZP was administered intravenously every four weeks.
On the primary endpoint measuring improvement of moderate-to-severe disease activity after 48 weeks, study participants receiving DZP plus standard care had a statistically significant 14.6% higher response rate (49.5%) than those receiving SOC alone (34.6%).
On the first secondary endpoint of disease activity response at Week 24, study participants receiving DZP plus SOC had a 7.9% higher response rate (46.6%) than those receiving SOC alone (38.3%). However, the difference did not reach statistical significance.
A greater response was observed across multiple clinical endpoints among participants treated with DZP, including 50% less severe disease flares than participants on standard of care alone.
Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
In 2024, UCB and Biogen will initiate a second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY.
From a stock perspective, William Blair writes that dapirolizumab isn&#8217;t significantly impacting Biogen&#8217;s valuation, as investors remain focused on Leqembi&#8217;s commercial rollout, which is still a work in progress.
The success of Biogen&#8217;s late-stage development programs is crucial for future growth, complementing opportunities from Leqembi, Skyclarys, and potentially zuranolone, especially as its multiple sclerosis business continues to feel pressure from generic competition.
Leqembi remains a growth driver, particularly with potential advancements like subcutaneous administration approval, though its progress has been slower than expected. Despite these challenges, Biogen&#8217;s modest valuation presents an upside, supported by its commercial portfolio and cost-cutting measures. The analyst maintains an <a target="_blank" href="https://www.benzinga.com/quote/biib/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a>
Price Action: BIIB stock is down 0.72% at $154.31 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42092265/stmicroelectronics-targets-18-billion-revenue-eyes-22-24-margins-by-2028" target="_blank" rel="noreferrer noopener">STMicroelectronics Targets $20 Billion Revenue By 2030, Unveils 2027 Goals</a></li>
</ul>

Analyst Color

Biotech

Equities

Health Care

Reiteration

Trading Ideas

General

UCBJF

UCBJY

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

<ul>
<li>Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity</li>
<li>A greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care alone</li>
<li>Systemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ systems, primarily in women, for whom there is a significant need for additional treatment options</li>
</ul>

UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction

Needham downgraded Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), citing limited catalysts for the company over the next year.
Alzheimer&#8217;s drug Leqembi&#8217;s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40774738/biogeneisais-leqembi-brings-hope-to-early-alzheimers-patients-amid-logistical-challenges" rel="noreferrer noopener">slow pace will continue</a>.
Leqembi&#8217;s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41626559/biogens-q3-profit-beats-expectations-on-lower-multiple-sclerosis-revenues-but-new-products-offset" rel="noreferrer noopener">approximately $39 million</a>.
Although investors are aware of this, market expectations are still high. Biogen will face ongoing challenges as these expectations are adjusted to more realistic levels.
In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and Biogen&#8217;s lecanemab for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41979127/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in-early-alzheim" rel="noreferrer noopener">early Alzheimer&#8217;s disease</a>.
Needham projects Skyclarys&#8217; fourth-quarter sales to reach approximately $116 million and $608 million for 2025. This aligns with management&#8217;s comments suggesting that U.S. sales growth may be uneven, while international growth could be slower due to pricing negotiations and a gradual increase in the number of patients on treatment.
Revenues from Skyclarys, acquired via Reata acquisition, reached $102.3 million during the quarter.
Needham writes that revenues are expected to remain flat or decline slightly until 2026, as it will take time for new products like Leqembi, Skyclarys, and Zurzuvae to grow enough to offset the drop in existing business.
Postpartum depression drug Zurzuvae&#8217;s third-quarter sales reached $22 million.
Needham has downgraded the stock from Buy to Hold with no price target, <a target="_blank" href="https://www.benzinga.com/quote/BIIB/analyst-ratings" rel="noreferrer noopener">compared to $270 earlier</a>.
Revenues are projected to fall by a small percentage in 2024, remain stable in 2025, and increase by about 3% in 2026, assuming continued growth from key product launches.
Operating margins are anticipated to improve by 80 basis points in 2025, driven by the Fit for Growth program, though this is already widely expected.
Business development could support growth in the short to medium term, but the timing and nature of such deals are hard to predict.
Price Action: BIIB stock is down 1.15% at $158.15 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42043081/why-is-medical-device-giant-boston-scientific-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?</a></li>
</ul>

Large Cap

Downgrades

ESALY

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Ami Fadia downgraded the rating for Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Buy to Hold and maintained the price target of $270. Biogen shares closed at $159.99 on Friday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Jacob Lacks downgraded the rating for Matson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) from Outperform to Peer Perform. Matson shares closed at $160.65 on Friday. <a href="https://www.benzinga.com/quote/MATX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Nicholas Campanella downgraded Pinnacle West Capital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) from Overweight to Equal-Weight and lowered the price target from $93 to $91. Pinnacle West Capital shares closed at $91.88 on Friday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Argus Research analyst John Eade downgraded the rating for Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) from Buy to Hold. Fortive shares closed at $74.82 on Friday. <a href="https://www.benzinga.com/quote/FTV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Nathan Jones downgraded Curtiss-Wright Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) from Buy to Hold and maintained the price target of $370. Curtiss-Wright shares closed at $358.35 on Friday. <a href="https://www.benzinga.com/quote/CW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BIIB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="548" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18081441/image-183-1024x548.png" alt="" class="wp-image-652880" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18081441/image-183-1024x548.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18081441/image-183-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18081441/image-183-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18081441/image-183.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Pre-Market Outlook

BFAM

MATX

This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

WIIM

Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.

Needham analyst Ami Fadia downgrades Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Buy to Hold and maintains the price target from $270 to $270.

Needham Downgrades Biogen to Hold, Maintains Price Target to $270

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BIIB usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Biogen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 26% leaning bullish and 66% bearish. Among these notable options, 2 are puts, totaling $80,703, and 13 are calls, amounting to $4,937,387.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $230.0 for Biogen, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Biogen options trades today is 1866.8 with a total volume of 4,855.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $110.0 to $230.0 over the last 30 days.
<h3>Biogen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731688345_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$1.5M</td>
<td>8.7K</td>
<td align="right">751</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$65.6</td>
<td>$65.5</td>
<td>$65.5</td>
<td>$110.00</td>
<td>$1.0M</td>
<td>8.7K</td>
<td align="right">896</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.6</td>
<td>$62.5</td>
<td>$62.5</td>
<td>$110.00</td>
<td>$625.0K</td>
<td>8.7K</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.5</td>
<td>$62.6</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$375.6K</td>
<td>8.7K</td>
<td align="right">231</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$319.2K</td>
<td>8.7K</td>
<td align="right">108</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
After a thorough review of the options trading surrounding Biogen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Biogen</h3>
<ul>
<li>Currently trading with a volume of 610,232, the BIIB's price is down by -2.38%, now at $160.97. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What The Experts Say On Biogen</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $219.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Biogen, targeting a price of $180. 
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Equal-Weight, adjusting the price target to $204. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $270. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Biogen, maintaining a target price of $255. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $190.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Biogen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Biogen Unusual Options Activity

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) from $36 to $41. Goldman Sachs analyst Andrea Tan maintained a Neutral rating. Tarsus Pharmaceuticals shares closed at $46.65 on Thursday. <a href="https://www.benzinga.com/quote/TARS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted the price target for The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from $115 to $131. Deutsche Bank analyst Bryan Kraft maintained a Buy rating. Disney shares closed at $109.12 on Wednesday. <a href="https://www.benzinga.com/quote/DIS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) price target from $125 to $145. Needham analyst Mayank Tandon maintained a Buy rating. Agilysys shares settled at $120.84 on Wednesday. <a href="https://www.benzinga.com/quote/AGYS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) price target from $240 to $225. Needham analyst Charles Shi maintained a Buy rating. Applied Materials shares closed at $186.00 on Thursday. <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">See how other analysts view this stock.</a></li>
<li></li>
<li>Piper Sandler boosted Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) price target from $565 to $575. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Mastercard shares closed at $520.40 on Thursday.  <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) price target from $55 to $60. Benchmark analyst Cody Acree maintained a Buy rating. Tower Semiconductor shares closed at $46.30 on Thursday. See how other analysts view this stock.</li>
<li>Morgan Stanley cut the price target for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from $23 to $9. Morgan Stanley analyst Andrew Percoco downgraded the stock from Equal-Weight to Underweight. SolarEdge shares settled at $12.83 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) price target from $294 to $300. Baird analyst Brian Skorney maintained an Outperform rating. Biogen shares closed at $164.89 on Thursday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from $385 to $425. Baird analyst Shrenik Kothari maintained an Outperform rating. Palo Alto shares closed at $394.39 on Thursday. <a href="https://www.benzinga.com/quote/PANW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Genelux Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) price target from $32 to $30. HC Wainwright &amp; Co. analyst Emily Bodnar maintained a Buy rating. Genelux shares closed at $2.94 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png" alt="" class="wp-image-650089" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170.png 1256w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

AGYS

AMAT

GNLX

PANW

SEDG

TARS

TSEM

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

Baird analyst Brian Skorney maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and raises the price target from $294 to $300.

Baird Maintains Outperform on Biogen, Raises Price Target to $300

Wolfe Research analyst Alexandria Hammond initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Biogen with Peer Perform Rating

<a href="https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi" title="https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi">https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi</a>

Global

ESAIY

ESALF

CHMP Recommends EU Approval For Eisai's Leqembi To Treat Early Alzheimer's Disease In Apolipoprotein E ε4 Non-Carriers And Heterozygotes; Leqembi, A Monoclonal Antibody, Shown To Slow Cognitive Decline

Throughout the last three months, 18 analysts have evaluated Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $249.94, along with a high estimate of $300.00 and a low estimate of $180.00. Observing a downward trend, the current average is 6.41% lower than the prior average price target of $267.06. 
<img src="https://www.benzinga.com/files/images/story/2024/1731596422_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Biogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$204.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Biogen. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Biogen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>Delving into Biogen's Background</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>A Deep Dive into Biogen's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Biogen's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -2.55%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Biogen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Biogen's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.41%, the company showcases efficient use of assets and strong financial health.
Debt Management: Biogen's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Biogen Through Analyst Insights

Citigroup analyst Geoff Meacham initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral rating and announces Price Target of $190.

Citigroup Initiates Coverage On Biogen with Neutral Rating, Announces Price Target of $190

In the preceding three months, 17 analysts have released ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $253.47, a high estimate of $300.00, and a low estimate of $180.00. Experiencing a 5.09% decline, the current average is now lower than the previous average price target of $267.06. 
<img src="https://www.benzinga.com/files/images/story/2024/1730736056_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Biogen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$204.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Biogen's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Biogen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>Delving into Biogen's Background</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Understanding the Numbers: Biogen's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Biogen displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 0.04%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biogen's net margin excels beyond industry benchmarks, reaching 15.76%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 2.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Biogen's ROA stands out, surpassing industry averages. With an impressive ROA of 1.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Biogen's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Biogen: Insights From 17 Financial Analysts

JP Morgan analyst Chris Schott maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $220 to $210.

JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $210

The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and the injection process is expected on average to take about 15 seconds. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly intravenous (IV) initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils&#x2A; which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain.

Reported Earlier, Eisai And Submit LEQEMBI BLA For Subcutaneous Alzheimer's Treatment To FDA, Targeting Early Disease Stages

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $270 to $255.

Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $255

Barclays analyst Carter Gould maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $190 to $180.

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $180

Biogen (BIIB – Research Report) received a Hold rating and price target from Needham analyst Ami Fadia today. The company's shares closed last Frid...

Needham downgrades Biogen (BIIB) to a Hold

How is QQQ stock faring? The Invesco QQQ ETF is down 3.07% in the past five days but has risen about 21.78% year-to-date. &nbsp; According to TipRa...

QQQ ETF Update, 11/18/2024

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Roku, Robinhood upgraded: Wall Street's top analyst calls

Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Spirit Airlines (SAVE) has entered int...

Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD...

UCB, Biogen present results from PHOENYCS GO study

Biogen, UCB release phase 3 data on lupus candidate dapirolizumab

How is VOO stock faring? The Vanguard S&P 500 ETF&nbsp;is up 0.24% in the past five days and has risen 31.36% over the past year. According to TipR...

VOO ETF Update, 11/20/2024

Mizuho lowered the firm's price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated models ...

Biogen price target lowered to $207 from $251 at Mizuho

Optimism over global healthcare sector rises: Jefferies

ABBV

AKRO

ALAB

AMGN

AMZN

APTV

BTBT

COMP

EONR

FTNT

GILD

HALO

HIMS

HOOD

HSBC

HUMA

INGM

LBRT

LRCX

MGIC

MPWR

MRNA

NFLX

NVDA

ODFL

PAYC

PAYX

PLTR

PRMB

RDFN

RGNX

ROKU

SAVE

SMCI

SNYNF

TSLA

TWST

Press Releases

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Management

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases

Legal

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Comments

Biogen

Vendite allo scoperto

Biogen (NASDAQ:BIIB) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO